Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Dyax completes BLA for DX-88 in hereditary angioedema

Sep. 29, 2008

Positive phase I interim results of XOMA-052 in type 2 diabetes

Sep. 29, 2008

Novel GIP antagonist shows efficacy in preclinical models of obesity and type 2 diabetes

Sep. 29, 2008

CHMP issues positive opinion for Kuvan for hyperphenylalaninemia

Sep. 26, 2008

Oramed commences phase IIa oral insulin trials in patients with type 1 diabetes

Sep. 26, 2008

Metabasis initiates MB-07803 trial in patients with type 2 diabetes

Sep. 26, 2008

Athersys provides update on ATHX-105 development and results of recent studies

Sep. 26, 2008

Akesis expands preclinical safety program for AKP-020

Sep. 26, 2008

Merck & Co reports results from studies with cathepsin K inhibitor odanacatib

Sep. 26, 2008

Recent patents describe novel agents for endocrine disorders

Sep. 25, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...